Researchers at Osaka University, Japan have reported a genome editing strategy that allowed mice to produce their own weight ...

Nuvalent Inc. (NASDAQ:NUVL) is one of the best mid cap pharma stocks to buy. On July 21, Nuvalent announced that the first ...

Scientists have gene-hacked mice to produce their own Ozempic-like enzymes, paving a path for humans to do so themselves one day. In a new study published in the journal Communications Medicine, ...

Data show that since the drugs were licensed there have been hundreds of cases of acute and chronic pancreatitis ...

Meanwhile, 101 reported reactions of this kind have been linked to exenatide, in which three people died. And 52 reported reactions of this sort have been linked to dulaglutide and 11 reported ...

Weekly injections of the GLP-1 receptor agonist exenatide (Byetta, Bydureon) did not slow Parkinson's disease progression or improve symptoms, the phase III Exenatide-PD3 trial showed.

Treatment with once-weekly exenatide was not associated with improvements in patients with Parkinson disease, according to findings from a study published in The Lancet.

"Vivani begins exenatide implant trial for obesity in Australia" was originally created and published by Medical Device Network, a GlobalData owned brand.

In a separate development, Amneal received FDA approval for exenatide, which is used alongside diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

BRIDGEWATER, N.J., November 21, 2024--Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist ...

A large-scale clinical trial found that intravenous infusion of exenatide, a glucagon-like peptide-1 (GLP-1) analog medication, during heart surgeries involving bypass did not significantly reduce ...

GLORIOUS: Neither Exenatide Nor Restrictive Oxygenation Boost CV Surgery Outcomes The two strategies, used to reduce renal, brain, and heart injury after surgery, were ineffective, but the story isn’t ...